Joe, just to kind of bring it altogether in terms of outlook because I think your question towards that will eventually turn to outlook. So again, let me just recalibrate. So if I take a step back, again, think about Q1, as I mentioned, earlier, we came in better than expected. Our EPS performance was better than expected. Coming into second quarter as I look at our outlook, look at our – look at the forward looking where we’re headed from Q2 and beyond. Our backlog position in Q2 supports the 0% to 2% organic, right? And then as I look forward and kind of think about sequentially 3Q, 4Q, HST is a $10 million ramp from 2 to 3, 3 to 4. And really, that’s driven by the backlog that we built for Mott that’s going to ship in the back half of the year, at this time that we are seeing in pharma, space and defense, okay. And FMT is pretty much going to be at the same levels and FSDP at the same levels of 2Q revenue to be able to get to an outlook of 1% to 3%. So, that’s on the top line. On the bottom line, though if you think about it, a third of our bottom line outlook is driven by the volume pieces I just articulated for you, but the two-thirds is tied to things that are in-flight in motion, i.e., cost optimization, de-layering stepping up in the back half. The cost out piece that we laid out for $20 million as part of this conversation that’s back half. And then the timing of share based comp from first half to second half, which is pretty significant, which is almost $0.12. So, again, a third of this first half, second half earnings ramp is tied to the revenue pieces I just laid out, two-thirds is tied to in-flight controllable actions that are part of this outlook.